SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases.
Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed to serving customers in this important market. For two decades, Illumina has been proud to partner with customers in China to advance genomics and improve human health.
"We are pleased with the announcement from MOFCOM, which is a very positive step forward. Illumina will continue to engage with authorities and stakeholders as we work toward a long-term resolution," said Jacob Thaysen, CEO of Illumina. "I want to thank our customers for their trust and support, and our team in China and around the world for their dedication and resilience."
Illumina is making no change to FY25 guidance, which was recently updated during the company's Q3 2025 earnings call.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Christine Douglass
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$120.45 |
| Daily Change: | -0.66 -0.54 |
| Daily Volume: | 376,740 |
| Market Cap: | US$18.510B |
October 15, 2025 September 23, 2025 September 03, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load